Spero Therapeutics, Inc. (SPRO)

NASDAQ: SPRO · IEX Real-Time Price · USD
1.92
+0.01 (0.52%)
At close: Dec 2, 2022 4:00 PM
1.93
+0.01 (0.52%)
After-hours: Dec 2, 2022 7:59 PM EST
0.52%
Market Cap 99.41M
Revenue (ttm) 8.81M
Net Income (ttm) -102.43M
Shares Out 35.88M
EPS (ttm) -3.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 415,120
Open 1.92
Previous Close 1.91
Day's Range 1.83 - 1.92
52-Week Range 0.68 - 16.3
Beta 0.77
Analysts Buy
Price Target 6.46 (+236.5%)
Earnings Date Nov 14, 2022

About SPRO

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720,... [Read more]

Industry Biotechnology
IPO Date Nov 2, 2017
CEO Ankit Mahadevia
Employees 41
Stock Exchange NASDAQ
Ticker Symbol SPRO
Full Company Profile

Financial Performance

In 2021, SPRO's revenue was $18.26 million, an increase of 95.67% compared to the previous year's $9.33 million. Losses were -$89.76 million, 14.7% more than in 2020.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for SPRO stock is "Buy." The 12-month stock price forecast is 6.46, which is an increase of 236.46% from the latest price.

Price Target
$6.46
(236.46% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Spero Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference

CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commer...

1 week ago - GlobeNewsWire

Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Misses Revenue Estimates

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 2.94% and 70.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

Spero Therapeutics Announces Third Quarter 2022 Operating Results and Provides Business Update

Entered into and closed exclusive license agreement with GSK for tebipenem HBr, pursuant to which Spero receives $66 million upfront, and a $9 million direct equity investment in Spero shares of common ...

2 weeks ago - GlobeNewsWire

Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBr

Pursuant to the agreement, Spero will be receiving a $66 million upfront payment, received a $9 million direct equity investment in shares of Spero common stock, and is eligible for potential future mil...

3 weeks ago - GlobeNewsWire

Spero Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on Monday, November 14,...

CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializin...

3 weeks ago - GlobeNewsWire

Spero Therapeutics, Inc. (SPRO) Expected to Beat Earnings Estimates: Should You Buy?

Spero Therapeutics, Inc. (SPRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Spero Therapeutics to Present Data at IDWeek 2022

CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializin...

1 month ago - GlobeNewsWire

Spero Therapeutics to Host Virtual R&D Event on Non-Tuberculous Mycobacterial Pulmonary Disease and the SPR720 Program

Event is taking place on Thursday, October 6 th at 11:30 a.m. ET

2 months ago - GlobeNewsWire

Spero (SPRO) Skyrockets 168% on Licensing Deal With GSK

The exclusive licensing agreement with GSK will fund Spero's (SPRO) existing operations and extend its current cash runway beyond 2024.

2 months ago - Zacks Investment Research

Spero's stock jumps 188% after GSK licenses experimental antibiotic

Shares of Spero Therapeutics Inc. SPRO, +277.39% soared 188.4% in trading on Thursday morning after the company signed an exclusive license agreement with GlaxoSmithKline GSK, -0.32% for its experimenta...

Other symbols: GSK
2 months ago - Market Watch

Spero Therapeutics (SPRO) Soars 137% on Exclusive License Agreement

Source: Willy Barton / Shutterstock.com Spero Therapeutics (NASDAQ: SPRO ) stock is rocketing higher on Thursday after the company signed a licensing agreement with GSK (NYSE: GSK ). This deal covers th...

2 months ago - InvestorPlace

GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr

The exclusive license allows GSK to commercialize tebipenem HBr in all territories, except Japan and certain other Asian countries

2 months ago - GlobeNewsWire

Spero Therapeutics Announces Appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer

Dr. Hamed has over 20 years of anti-infective experience and has spearheaded the global development and approval of multiple anti-infective products Dr. Hamed has over 20 years of anti-infective experie...

2 months ago - GlobeNewsWire

Spero (SPRO) Up Following Positive FDA Update for UTI Drug

Spero (SPRO) surges on achieving common ground with the FDA on the regulatory path forward for tebipenem HBr.

2 months ago - Zacks Investment Research

Why Is Spero Therapeutics (SPRO) Stock Up 15% Today?

Source: Shutterstock Spero Therapeutics (NASDAQ: SPRO ) stock is climbing higher on Wednesday thanks to positive feedback from the FDA. That concerns plans to resubmit tebipenem HBr for the treatment of...

2 months ago - InvestorPlace

Spero Therapeutics to Present at Upcoming Investor Conference

CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializin...

2 months ago - GlobeNewsWire

Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Adminis...

Alignment with the FDA on a regulatory path forward for the continued development of tebipenem Hbr

2 months ago - GlobeNewsWire

Spero Therapeutics, Inc. (SPRO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Spero Therapeutics, Inc. (SPRO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions c...

3 months ago - Zacks Investment Research

Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Misses Revenue Estimates

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 1.14% and 13.35%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Spero Therapeutics Announces Second Quarter 2022 Operating Results and Provides Business Update

Initiation of a Placebo-controlled Phase 2 Trial of SPR720 in Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) Expected in 4Q 2022

3 months ago - GlobeNewsWire

Spero Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results on Wednesday, August 1...

CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Wednesday, August 10, 2022 at 4:...

3 months ago - GlobeNewsWire

SHAREHOLDER ALERT FILING DEADLINE TODAY: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in S...

NEW YORK , July 25, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Spero Therapeutics, Inc. ("Spero" or the "Company") (NASDAQ: SPRO) and certain of its ...

4 months ago - PRNewsWire

SPRO FINAL DEADLINE TODAY: ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Spero Therapeutics, Inc. Investors with Loss...

New York, New York--(Newsfile Corp. - July 25, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spero Therapeutics, Inc. (NASDAQ: SPRO) between May...

4 months ago - Newsfile Corp

Bronstein, Gewirtz & Grossman, LLC Reminds Spero Therapeutics, Inc. (SPRO) Shareholders of Class Action Deadline and ...

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Spero Therapeutics, Inc. (“Spero” or the “Compan...

4 months ago - Business Wire

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Spero Therapeutics, Inc. with Losses of $100,000 to Conta...

Los Angeles, California--(Newsfile Corp. - July 25, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Spero Therapeutics, In...

4 months ago - Newsfile Corp